BackParatek Pharmaceuticals Overview

Paratek Pharmaceuticals Long Term Debt

Track Paratek Pharmaceuticals's long-term debt ($96M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$95.71M
↓ 62.78% YoYΔ $-161.44M vs prior year quarter

Peer average

Loading

Paratek Pharmaceuticals Long Term Debt History

Loading

Paratek Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Paratek Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Paratek Pharmaceuticals (PRTK) FAQ

As of the most recent data (June 2023), PRTK shows a long-term debt of $96M. That compares with $260M in the prior-year period — down 62.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PRTK's long-term debt is now $96M (was $260M) — a 62.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Paratek Pharmaceuticals is outperforming or lagging.

Tracking PRTK's long-term debt over time shows whether Paratek Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $96M That compares with $260M in the prior-year period — down 62.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Paratek Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $96M) with ownership activity and broader fundamentals.

Paratek Pharmaceuticals's long-term debt is $96M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.